MARCH 2023LIFE SCIENCES REVIEW 19commercial process. It aims to understand and mitigate any significant risks related to clinical manufacturing activities. This includes complying with regulations, time-to-market planning, required development studies to ensure the success of commercial production, validation, and maintaining a secure supply chain when transitioning from clinical to commercial production.Its experience in scaling up, along with in-house research and development and manufacturing capabilities, enables the organization to efficiently anticipate and minimize these risks, simplifying the transition process. Particularly, for supply chain security, the method of serialization and aggregation for packaging allows it to help secure the supply chain for its partners.The difference in AbbVie's approach translates primarily into time savings. It holds more experience in dealing with manufacturing hurdles, data transfer issues, regulatory obstacles, and quality concerns. Data and reports are essential before submitting an NDA or biologics license application (BLA), or the risks involved in seeking approval. By partnering with a CMO like AbbVie, a company can receive more informed guidance and get their product to the market faster.AbbVie Contract Manufacturing's proficiency in achieving impactful outcomes is rooted in its systematic client engagement approach, typically initiated with a thorough examination of the client's priorities. The process is characterized by a meticulous exploration to gain a comprehensive understanding of the client's specific needs, the intricacies of their manufacturing requirements, and any unique elements that define their project. This structured methodology serves as a foundation for forging successful partnerships by ensuring a clear alignment between AbbVie's capabilities and the distinctive requirements of its clients.Following this exchange, AbbVie proceeds to examine its technical capabilities to ensure compatibility with the client's specific needs. In the wake of these preliminary discussions, if mutual satisfaction prevails, it formalizes a confidentiality disclosure agreement (CDA) and ventures into more comprehensive discussions. Besides, during these preliminary interactions, it ensures its purposes are in harmony with the client's aspirations. This reciprocity is the linchpin of the company's partnership, as technical compatibility alone may not suffice.Culture plays a pivotal role in any organization, and at AbbVie, it stands as a central pillar. What distinguishes AbbVie's culture is its resounding dedication to patient centricity. The guiding principle here is that every decision and every action is undertaken with the patient's well-being at the forefront. We, AbbVie Contract Manufacturing, are at the forefront in addressing these challenges, not just as a CMO, but a reliable partner for advancing pharmaceutical excellence and securing the continuous flow of medicine to patients, fortified by our profound expertise and foresight
< Page 9 | Page 11 >